European Companies Search Engine
EU funding (€9,983,029): Immune profiling to guide host-directed interventions to cure HBV infections Hor1 Jan 2020 EU Research and Innovation programme "Horizon"
Text
Immune profiling to guide host-directed interventions to cure HBV infections
The objective of the project is to develop novel curative concepts for chronic hepatitis B (CHB). Specific aims will be to: 1) improve the rate of functional cure of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine; ii) characterize immune and viral biomarker signatures for patient stratification and treatment response monitoring; iii) integrate biological and clinical data to model the best combination treatment for future trials; iv) model the effectiveness of novel curative therapies with respect to disease spectrum, patient heterogeneity, and constraints of National Health Systems. The project organization will combine: i) a Proof of Concept clinical trial of a combination of 2 novel compounds stimulating innate immunity; ii) a preclinical immune therapy platform in humanized mice combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses; iii) extensive virologic and immune profiling to identify correlates of cure in patients, iv) the integration of large biological and clinical datasets, v) a cost-effectiveness modelling of new therapeutic interventions, vi) project management, vii) results exploitation and dissemination. The proposal responds to the work program by: i) including the evaluation of emerging concepts in drug and vaccine development to discover a curative strategy for CHB, a major public health concern for Europe, ii) capitalizing on knowledge of host-pathogen interactions to develop novel immune-based therapies, iii) considering age, gender and viral genetic variations, iv) comprising a clinical trial and a pre-clinical platform for the discovery of novel immune interventions, and selection of relevant biomarkers for validation in established clinical cohorts, v) addressing conditions for effective uptake of the new curative interventions by National Health Systems.
Funded Companies:
| Company name | Funding amount |
| €0.00 | |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | €690,049 |
| CHU Hopitaux de Bordeaux | €0.00 |
| €30,379 | |
| European Liver Patients Association | €175,000 |
| Fondazione Irccs CA' Granda - Ospedale Maggiore Policlinico | €198,538 |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | €211,444 |
| Gilead Sciences Inc. | €0.00 |
| Hospices Civils de Lyon | €200,000 |
| Inserm Transfert SA | €300,000 |
| Institut National de la Sante et de la Recherche Medicale | €4,324,129 |
| Institut Pasteur | €1,593,800 |
| Karolinska Institutet | €299,550 |
| UNIVERSITAETSKLINIKUM FREIBURG | €863,401 |
| Universita Degli Studi DI Parma | €1,096,740 |
| Universite Grenoble Alpes | €0.00 |
Source: https://cordis.europa.eu/project/id/847939
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Azienda Ospedaliero-Universitaria DI Parma - EU funding (€9,983,029): Immune profiling to guide host-directed interventions to cure HBV infections"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
